GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneOne Life Science Inc (XKRX:011000) » Definitions » Change In Receivables

GeneOne Life Science (XKRX:011000) Change In Receivables : ₩-1,513 Mil (TTM As of Mar. 2025)


View and export this data going back to 1987. Start your Free Trial

What is GeneOne Life Science Change In Receivables?

GeneOne Life Science's change in receivables for the quarter that ended in Mar. 2025 was ₩2,697 Mil. It means GeneOne Life Science's Accounts Receivable declined by ₩2,697 Mil from Dec. 2024 to Mar. 2025 .

GeneOne Life Science's change in receivables for the fiscal year that ended in Dec. 2024 was ₩387 Mil. It means GeneOne Life Science's Accounts Receivable declined by ₩387 Mil from Dec. 2023 to Dec. 2024 .

GeneOne Life Science's Accounts Receivable for the quarter that ended in Mar. 2025 was ₩4,932 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. GeneOne Life Science's Days Sales Outstanding for the three months ended in Mar. 2025 was 52.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. GeneOne Life Science's liquidation value for the three months ended in Mar. 2025 was ₩-51,885 Mil.


GeneOne Life Science Change In Receivables Historical Data

The historical data trend for GeneOne Life Science's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneOne Life Science Change In Receivables Chart

GeneOne Life Science Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,888.64 1,001.35 414.81 5,534.10 387.07

GeneOne Life Science Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,597.50 -3,755.04 494.76 -950.16 2,697.13

GeneOne Life Science Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,513 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneOne Life Science  (XKRX:011000) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

GeneOne Life Science's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4931.639/8503.754*91
=52.92

2. In Ben Graham's calculation of liquidation value, GeneOne Life Science's accounts receivable are only considered to be worth 75% of book value:

GeneOne Life Science's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3944.293-67855.24+0.75 * 4931.639+0.5 * 16653.775
=-51,885

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GeneOne Life Science Change In Receivables Related Terms

Thank you for viewing the detailed overview of GeneOne Life Science's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneOne Life Science Business Description

Traded in Other Exchanges
N/A
Address
343, Hakdong-ro, Gangnam-Gu, Seoul, KOR
GeneOne Life Science Inc is engaged in the research, development, and manufacturing of biopharmaceutical products including vaccines for treating pandemic influenza, seasonal influenza for old people, and chronic hepatitis B and C as well cancers and other infectious diseases.

GeneOne Life Science Headlines

No Headlines